Politecnico di Torino - Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY

+39 011 090 6100 info@tech-share.it

IMPAVID – Polymeric scaffold for cardiac regeneration

Biodegradable scaffoldsCardiac regenerationCardioprotectionCardioprotezioneIntelligent nanoparticlesStem cell recruitment


The object of the present invention consists of a polymeric scaffold capable of mediating cardiac regeneration. Moreover, it can protect from reperfusion injury using cardioprotective agents that can be loaded on the biomatrix. The device is called IMPAVID (Intelligent Microfabricated PAtches able to recruit stem cells and control reperfusion injury process for in VIvo myocarDial implantation).

Technical features

Cardiovascular disease (CVD) is the single largest cause of death worldwide. Current therapy for CVD is based on drugs, coronary artery bypass graft and angioplasty procedures; however, such therapies do not restore the functionality of damaged myocardial tissue. In addition, while use of thrombolytics and balloon angioplasty to rapidly reperfuse heart tissue with oxygen has to date greatly reduced morbidity and mortality, paradoxically, about 50% of the damage to heart tissue following myocardial infarction is a result of re-oxygenation. The logic of this technology is to solve the problem by putting together two actions. IMPAVID is an in vivo myocardial tissue engineering technology capable of simultaneously providing in situ regeneration by implantation of cardiac patches and activation of endogenous stem cells and protection of myocardium from reperfusion injury using small cardioprotective molecules. IMPAVID’s in vivo approach poses the most ambitious challenges, but it is also the most attractive option for the global market.

Possible Applications

  • New therapy for cardiac tissue regeneration;
  • Localized cardioprotective drug delivery system;
  • Intelligent scaffold for tissue repair after myocardial infarction;
  • Nanotechnology for in situ control of stem cell niche.


  • Use of materials independent on the individuality of each patient;
  • Immediate applicability of the device without delays due to cell culturing (the only opportunity to address the acute phase);
  • Higher product transportability and storage as compared with cellularized scaffolds;
  • Complete feasibility within industrial facilities.